Osiris Therapeutics, Inc. – Product Pipeline Review – 2012


December 31, 2012
53 Pages - SKU: GMD4939528
License type:
Table of Contents Search inside this report Related Reports


Osiris Therapeutics, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Osiris Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the Osiris Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Osiris Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Osiris Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Osiris Therapeutics, Inc. - Brief Osiris Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Osiris Therapeutics, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Osiris Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Osiris Therapeutics, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Osiris Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Osiris Therapeutics, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Osiris Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Osiris Therapeutics, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Osiris Therapeutics, Inc. and identify potential opportunities in those areas.


Osiris Therapeutics, Inc. Snapshot
Osiris Therapeutics, Inc. Overview
Key Information
Key Facts
Osiris Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Osiris Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Osiris Therapeutics, Inc. – Pipeline Products Glance
Osiris Therapeutics, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Osiris Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Osiris Therapeutics, Inc. – Drug Profiles
Chondrogen
Product Description
Mechanism of Action
R&D Progress
Osteocel-XC
Product Description
Mechanism of Action
R&D Progress
remestemcel-L
Product Description
Mechanism of Action
R&D Progress
Osiris Therapeutics, Inc. – Pipeline Analysis
Osiris Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Osiris Therapeutics, Inc. – Pipeline Products by Route of Administration
Osiris Therapeutics, Inc. – Recent Pipeline Updates
Osiris Therapeutics, Inc. - Dormant Projects
Osiris Therapeutics, Inc. – Company Statement
Osiris Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Osiris Therapeutics, Inc., Recent Developments
Osiris Therapeutics, Inc.- Press Release
Sep 28, 2012: Osiris Therapeutics Regains Worldwide Rights To Chondrogen
Sep 28, 2012: Osiris Therapeutics Regains Worldwide Rights To Prochymal
Sep 28, 2012: Osiris Therapeutics's Prochymal To Be Evaluated Under Swissmedic's Rapid Authorization Procedures
Jul 02, 2012: Osiris Therapeutics's Prochymal Significantly Reduces Hypertrophy, Arrhythmia And Progression To Heart Failure In Patients Suffering Heart Attack
Jun 29, 2012: Osiris Annouces Expansion Of Intellectual Property Protection Covering Prochymal
Jun 14, 2012: Osiris Receives Second Approval for Life-Saving Stem Cell Drug Prochymal
May 17, 2012: Osiris Receives Marketing Clearance From Health Canada For Prochymal
Jan 03, 2012: Osiris Therapeutics Provides Update On Stem Cell Trial For Type 1 Diabetes
Dec 02, 2009: Osiris Reports Positive Two-Year Data On Stem Cell Treatment For Acute Myocardial Infarction
Sep 08, 2009: Osiris Therapeutics Announces Preliminary Results For Prochymal Phase III GvHD Trials
Sep 08, 2009: Osiris' Stem Cell Drug Fails In Two Late-Stage Trials
Jul 28, 2009: Osiris Achieves Milestone Payment For Progress Developing Stem Cell Therapy For Prochymal
Jun 23, 2009: Osiris Therapeutics Reports Interim Data For COPD Stem Cell Study
Apr 17, 2009: Osiris Completes Enrollment In Second Prochymal Phase III Trial For Graft vs. Host Disease
Apr 02, 2009: Osiris Treates First Patient In Phase II Stem Cell Trial For Heart Attacks
Mar 27, 2009: Osiris Discontinues Enrollment In Crohn's Study Due To Concerns With Trial Design
Jan 15, 2009: Osiris and FDA Reach Agreement On Submission Of First Marketing Application For A Stem Cell Product
Financial Deals Landscape
Osiris Therapeutics, Inc., Deals Summary
Osiris Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Genzyme Enters Into Agreement With Osiris Therapeutics
Osiris Therapeutics Enters Into An Agreement With Juvenile Diabetes Research Foundation International
Osiris Therapeutics Enters Into An Agreement With Genzyme
Equity Offering
Osiris Therapeutics Completes Private Placement Of $12 Million
Osiris Therapeutics Completes Private Placement Of $20 Million
Osiris Completes IPO Of $38.5 Million
Debt Offering
Osiris Therapeutics Completes Private Placement Of Convertible Debt For $20 Million
Asset Transactions
NuVasive Acquires Osteocel Business From Osiris Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Osiris Therapeutics, Inc., Key Information
Osiris Therapeutics, Inc., Key Facts
Osiris Therapeutics, Inc. – Pipeline by Indication, 2012
Osiris Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Osiris Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Osiris Therapeutics, Inc. – Phase III, 2012
Osiris Therapeutics, Inc. – Phase II, 2012
Osiris Therapeutics, Inc. – Phase I, 2012
Osiris Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Osiris Therapeutics, Inc. – Pipeline By Route of Administration, 2012
Osiris Therapeutics, Inc. – Recent Pipeline Updates, 2012
Osiris Therapeutics, Inc. - Dormant Developmental Projects,2012
Osiris Therapeutics, Inc., Deals Summary
Genzyme Enters Into Agreement With Osiris Therapeutics
Osiris Therapeutics Enters Into An Agreement With Juvenile Diabetes Research Foundation International
Osiris Therapeutics Enters Into An Agreement With Genzyme
Osiris Therapeutics Completes Private Placement Of $12 Million
Osiris Therapeutics Completes Private Placement Of $20 Million
Osiris Completes IPO Of $38.5 Million
Osiris Therapeutics Completes Private Placement Of Convertible Debt For $20 Million
NuVasive Acquires Osteocel Business From Osiris Therapeutics
List of Figures
Osiris Therapeutics, Inc. – Pipeline by Indication, 2012
Osiris Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Osiris Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Osiris Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Osiris Therapeutics, Inc. – Pipeline By Route of Administration, 2012

More Biotechnology Company reports by Global Markets Direct

Novartis AG – Product Pipeline Review – 2012 by Global Markets Direct
Novartis AG – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Novartis AG - Product Pipeline Review - 2012” provides data on the Novartis ...
VasGene Therapeutics, Inc. – Product Pipeline Review – 2012 by Global Markets Direct
VasGene Therapeutics, Inc. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “VasGene Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on ...
Generex Biotechnology Corporation – Product Pipeline Review – 2012 by Global Markets Direct
Generex Biotechnology Corporation – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Generex Biotechnology Corporation - Product Pipeline Review - 2012” provides data on ...
CytoGenix, Inc. – Product Pipeline Review – 2012 by Global Markets Direct
CytoGenix, Inc. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “CytoGenix, Inc. - Product Pipeline Review - 2012” provides data on the CytoGenix, ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Biotechnology Company Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!